MedTrace Logo

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML

NCT05272293 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-08-28

No results posted yet for this study

Summary

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.

Conditions

Interventions

BIOLOGICAL

NK cell infusions

Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).

Sponsors & Collaborators

  • Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

    lead OTHER

Principal Investigators

  • Olga Aleinikova, MD, Prof · Belarussian Research Center for Pediatric Oncology, Hematology and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Belarus

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272293 on ClinicalTrials.gov